Latest Information Update: 18 Feb 2008
At a glance
- Originator Palatin Technologies
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Bacterial infections
Most Recent Events
- 05 Oct 2001 No-Development-Reported for Diagnostic imaging in Japan (Unknown route)
- 03 Dec 1998 Preclinical development for Diagnostic imaging in Japan (Unknown route)